Payment overview · 2025
General Payments
$147.86
9 reported records · 9 companies
Healthcare provider profile · identity verified
Robert Brinkman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FOLSOM, LA · NPI 1881614865
Verified facts
What the public records show
CMS Open Payments records show Robert Brinkman, M.D. received $147.86 in general payments during 2025 across 9 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.56 | 13.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.00 | 12.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.19 | 11.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.69 | 11.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.68 | 11.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.03 | 10.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.88 | 10.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.29 | 9.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.54 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $147.86 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 493 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 469 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 468 | 155 |
| Pantoprazole Sodium | Pantoprazole Sodium | 352 | 122 |
| Alprazolam | Alprazolam | 318 | 64 |
| Gabapentin | Gabapentin | 235 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 224 | 70 |
| Metformin Hcl Er | Metformin Hcl | 201 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 199 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 198 | 81 |
| Omeprazole | Omeprazole | 195 | 59 |
| Metformin Hcl | Metformin Hcl | 187 | 60 |
| Lisinopril | Lisinopril | 185 | 62 |
| Losartan Potassium | Losartan Potassium | 183 | 60 |
| Ozempic | Semaglutide | 178 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 155 | 34 |
| Simvastatin | Simvastatin | 152 | 48 |
| Glimepiride | Glimepiride | 150 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 44 |
| Ramipril | Ramipril | 146 | 46 |
| Furosemide | Furosemide | 143 | 40 |
| Clonazepam | Clonazepam | 142 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 48 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 133 | 47 |
| Lorazepam | Lorazepam | 123 | 27 |
| Trazodone Hcl | Trazodone Hcl | 122 | 40 |
| Montelukast Sodium | Montelukast Sodium | 116 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 106 | 30 |
| Carvedilol | Carvedilol | 104 | 28 |
| Potassium Chloride | Potassium Chloride | 98 | 35 |
| Allopurinol | Allopurinol | 97 | 39 |
| Synthroid | Levothyroxine Sodium | 90 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 88 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 24 |
| Jardiance | Empagliflozin | 86 | 20 |
| Tramadol Hcl | Tramadol Hcl | 86 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 23 |
| Sertraline Hcl | Sertraline Hcl | 84 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 81 | 31 |
| Famotidine | Famotidine | 76 | 24 |
| Atenolol | Atenolol | 75 | 23 |
| Azelastine Hcl | Azelastine Hcl | 72 | 38 |
| Celecoxib | Celecoxib | 71 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 23 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 69 | suppressed |
| Meloxicam | Meloxicam | 69 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 42 |
| Mounjaro | Tirzepatide | 67 | 13 |
| Eliquis | Apixaban | 63 | 17 |
| Estradiol | Estradiol | 63 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 18 |
| Alendronate Sodium | Alendronate Sodium | 59 | 20 |
| Valacyclovir | Valacyclovir Hcl | 56 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 54 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 51 | 26 |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Aripiprazole | Aripiprazole | 50 | 15 |
| Temazepam | Temazepam | 50 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 21 |
| Sucralfate | Sucralfate | 48 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 12 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Ezetimibe | Ezetimibe | 44 | 19 |
| Irbesartan | Irbesartan | 44 | 11 |
| Pregabalin | Pregabalin | 44 | 12 |
| Cefuroxime | Cefuroxime Axetil | 43 | 35 |
| Fenofibrate | Fenofibrate | 42 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Linzess | Linaclotide | 41 | 16 |
| Prednisone | Prednisone | 41 | 32 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 13 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 21 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Glipizide Er | Glipizide | 36 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 11 |
| Diazepam | Diazepam | 35 | 11 |
| Meclizine Hcl | Meclizine Hcl | 34 | 17 |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Mirtazapine | Mirtazapine | 32 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Donepezil Hcl | Donepezil Hcl | 31 | 12 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | 11 |
| Glipizide | Glipizide | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Finasteride | Finasteride | 29 | 11 |
| Methylprednisolone | Methylprednisolone | 27 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | 13 |
| Valsartan | Valsartan | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $147.86 · 9 records | Bayer Healthcare Pharmaceuticals Inc. | Cologuard Collection Kit, FARXIGA, GEMTESA, JARDIANCE, KRYSTEXXA, Kerendia, MOUNJARO, NURTEC ODT, Veozah, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error